98 related articles for article (PubMed ID: 35509237)
1. A UK consensus algorithm for early treatment modification in newly diagnosed systemic light-chain amyloidosis.
Ravichandran S; Mahmood S; Wisniowski B; Sachchithanantham S; Popat R; Lachmann H; Rabin N; Ramasamy K; Hawkins S; Kyriakou C; Gillmore J; Yong K; Hawkins P; Jackson G; Pratt G; D Wechalekar A
Br J Haematol; 2022 Jul; 198(2):328-332. PubMed ID: 35509237
[TBL] [Abstract][Full Text] [Related]
2. [A clinical retrospective analysis of newly diagnosed multiple myeloma patients with systemic light chain amyloidosis].
Liu Y; You HY; Yan LZ; Jin S; Shang JJ; Shi XL; Yan S; Yao WQ; Wu DP; Liu W; Fu CC
Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):330-335. PubMed ID: 35680633
[No Abstract] [Full Text] [Related]
3. Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2024 Feb; 99(2):309-324. PubMed ID: 38095141
[TBL] [Abstract][Full Text] [Related]
4. [AL Amyloidosis].
Ueda M
Brain Nerve; 2024 May; 76(5):583-587. PubMed ID: 38741500
[TBL] [Abstract][Full Text] [Related]
5. Bad players in AL amyloidosis in the current era of treatment.
Kreiniz N; Gertz MA
Expert Rev Hematol; 2023 Jan; 16(1):33-49. PubMed ID: 36620914
[TBL] [Abstract][Full Text] [Related]
6. How I Approach Light Chain Amyloidosis.
Chowdhury RB; Leung N
G Ital Nefrol; 2023 Oct; 40(Suppl 81):. PubMed ID: 38007836
[TBL] [Abstract][Full Text] [Related]
7. Impact of light chain isotype on clinical features and outcomes in systemic AL amyloidosis.
Hopson MB; Bhutani D; Sarkaria S; Maurer MS; Griffin JM; Mapara M; Lentzsch S; Chakraborty R
Leuk Lymphoma; 2022 Sep; 63(9):2109-2113. PubMed ID: 35465769
[TBL] [Abstract][Full Text] [Related]
8. Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis.
Gustine JN; Staron A; Mendelson L; Joshi T; Gopal DM; Siddiqi OK; Ruberg FL; Sanchorawala V
Blood Adv; 2023 Oct; 7(20):6080-6091. PubMed ID: 37581513
[TBL] [Abstract][Full Text] [Related]
9. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018.
Gertz MA
Blood Cancer J; 2018 May; 8(5):44. PubMed ID: 29795248
[TBL] [Abstract][Full Text] [Related]
10. [Light chain amyloidosis].
Hegenbart U; Aus dem Siepen F; Schönland S
Inn Med (Heidelb); 2023 Sep; 64(9):842-847. PubMed ID: 37540260
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis.
Cohen OC; Ismael A; Pawarova B; Manwani R; Ravichandran S; Law S; Foard D; Petrie A; Ward S; Douglas B; Martinez-Naharro A; Chacko L; Quarta CC; Mahmood S; Sachchithanantham S; Lachmann HJ; Hawkins PN; Gillmore JD; Fontana M; Falk RH; Whelan CJ; Wechalekar AD
Eur Heart J; 2022 Jan; 43(4):333-341. PubMed ID: 34472567
[TBL] [Abstract][Full Text] [Related]
12. Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group.
Maurer MS; Dunnmon P; Fontana M; Quarta CC; Prasad K; Witteles RM; Rapezzi C; Signorovitch J; Lousada I; Merlini G
Circ Heart Fail; 2022 Jun; 15(6):e009038. PubMed ID: 35331001
[TBL] [Abstract][Full Text] [Related]
13. Individualized Approach to Management of Light Chain Amyloidosis.
Palladini G; Milani P
J Natl Compr Canc Netw; 2023 Jan; 21(1):91-98. PubMed ID: 36634608
[TBL] [Abstract][Full Text] [Related]
14. Chinese consensus on the diagnosis and treatment of immunoglobulin light-chain cardiac amyloidosis.
Shen K; Tian Z; Gao Y; Wang Y; Huo L; Li J; Zhang Y; Zhang S;
Chin Med J (Engl); 2024 Jan; 137(2):127-129. PubMed ID: 38146261
[No Abstract] [Full Text] [Related]
15. Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis.
Ravichandran S; Law S; Mahmood S; Wisniowski B; Foard D; Fontana M; Martinez-Naharro A; Whelan C; Gillmore JD; Lachmann HJ; Hawkins PN; Wechalekar AD
Leukemia; 2022 Apr; 36(4):1180-1184. PubMed ID: 34987193
[No Abstract] [Full Text] [Related]
16. Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis.
Ikura H; Endo J; Kitakata H; Moriyama H; Sano M; Fukuda K
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35683015
[TBL] [Abstract][Full Text] [Related]
17. Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival.
Basset M; Milani P; Foli A; Nuvolone M; Benvenuti P; Nanci M; Fabris F; Bellofiore C; Merlini G; Palladini G
Blood; 2022 Nov; 140(18):1964-1971. PubMed ID: 35772003
[TBL] [Abstract][Full Text] [Related]
18. Serum monoclonal immunoglobulin light-chain detection differs between immunofixation electrophoresis methods in patients with AL amyloidosis.
Kawano Y; Nishimura N; Yasunaga JI
Int J Hematol; 2024 May; ():. PubMed ID: 38739302
[TBL] [Abstract][Full Text] [Related]
19. Validation of an administrative coding algorithm for the identification of individuals with amyloid light chain amyloidosis using administrative data.
Jimenez-Zepeda VH; Reece D; Rigo R; Gogna P; Kong S; Hu XY; Chapani P; Cheung WY; Brenner DR; Plante R; Shi K; Husain A; Ammann E; Tankala D; Boyne DJ
Leuk Lymphoma; 2023 Jan; 64(1):256-258. PubMed ID: 36409003
[No Abstract] [Full Text] [Related]
20. Epidemiology and clinical outcomes of light-chain amyloidosis in Sweden: A nationwide population-based study.
Mellqvist UH; Cai Q; Hester LL; Grövdal M; Börsum J; Rahman I; Ammann EM; Hansson M
Eur J Haematol; 2023 Nov; 111(5):697-705. PubMed ID: 37533343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
